Skip to main content

RenovoRx, Inc.

corporate_fare Company Profile

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RenovoRx Registers Resale of 15.9 Million Shares from Recent Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RenovoRx Registers Over $20 Million in Shares and Warrants for Resale by Private Placement Investors
Sentiment: Negative
View Wiseek Article
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RenovoCath Device Secures First Japanese Patent Allowance, Bolstering Global IP and Asia Expansion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
Sentiment: Positive
View Wiseek Article
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility
Sentiment: Positive
View Wiseek Article
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RenovoRx CEO Invests $27,702 in Company's Recently Closed Private Placement
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
CFO Mark Voll Invests $110,808 in RenovoRx Through Private Placement, Acquiring Stock and Warrants
Sentiment: Positive
View Wiseek Article
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RenovoRx Secures $10M Private Placement to Fund Commercialization and Phase III Trial
Sentiment: Positive
View Wiseek Article
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Secures $10M Private Placement, Issuing ~10.6M Shares and Warrants
Sentiment: Neutral
View Wiseek Article
RNXT
Feb 27, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
RenovoRx Triples Cancer Center Adoption of RenovoCath, Appoints Executive Chairman to Drive Commercial Growth
Sentiment: Positive
View Wiseek Article
RNXT
Feb 06, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
RenovoRx Appoints Experienced Public Company Executive Mark Voll as CFO
Sentiment: Positive
View Wiseek Article
RNXT
Jan 02, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
9
RenovoRx Receives Nasdaq Deficiency Notice for Failing Minimum Bid Price Requirement
Sentiment: Negative
View Wiseek Article